- Home
- IDYA vs PRM Comparison
IDYA vs PRM Comparison
Compare IDYA & PRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- PRM
- Stock Information
- Founded
- IDYA 2015
- PRM 2018
- Country
- IDYA United States
- PRM United States
- Employees
- IDYA N/A
- PRM N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- PRM Newspapers/Magazines
- Sector
- IDYA Health Care
- PRM Consumer Discretionary
- Exchange
- IDYA Nasdaq
- PRM Nasdaq
- Market Cap
- IDYA 2.0B
- PRM N/A
- IPO Year
- IDYA 2019
- PRM N/A
- Fundamental
- Price
- IDYA $17.05
- PRM $10.41
- Analyst Decision
- IDYA Strong Buy
- PRM Strong Buy
- Analyst Count
- IDYA 13
- PRM 2
- Target Price
- IDYA $53.58
- PRM $16.00
- AVG Volume (30 Days)
- IDYA 887.8K
- PRM 1.3M
- Earning Date
- IDYA 05-06-2025
- PRM 05-08-2025
- Dividend Yield
- IDYA N/A
- PRM N/A
- EPS Growth
- IDYA N/A
- PRM N/A
- EPS
- IDYA N/A
- PRM N/A
- Revenue
- IDYA $7,000,000.00
- PRM $560,968,000.00
- Revenue This Year
- IDYA $89.14
- PRM N/A
- Revenue Next Year
- IDYA $291.34
- PRM $5.01
- P/E Ratio
- IDYA N/A
- PRM N/A
- Revenue Growth
- IDYA N/A
- PRM 74.16
- 52 Week Low
- IDYA $16.88
- PRM $6.84
- 52 Week High
- IDYA $44.42
- PRM $14.44
- Technical
- Relative Strength Index (RSI)
- IDYA 31.80
- PRM 54.52
- Support Level
- IDYA $17.05
- PRM $8.97
- Resistance Level
- IDYA $18.90
- PRM $10.77
- Average True Range (ATR)
- IDYA 0.91
- PRM 0.37
- MACD
- IDYA 0.01
- PRM 0.25
- Stochastic Oscillator
- IDYA 6.27
- PRM 75.40
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.